Kura Oncology's Ziftomenib Approval Receives Positive Reactions from Barclays and the FDA

Kura Oncology (KURA) stock is expected to double in 2026 after Barclays analyst Etzer Darout raised the price target to $28 from $11 and maintained an Overweight rating. The approval of ziftomenib, a treatment for relapsed or refractory acute myeloid leukemia, is seen as a significant factor in this prediction. The approval was based on data from the pivotal KOMET-001 trial, which demonstrated compelling efficacy and a favorable safety profile.